Arrogene, Inc., an Oncology Biotherapeutics Company, was founded by scientists in the Departments of Neurosurgery and Surgery at Cedars-Sinai Medical Center. Arrogene has designed a novel effective anti-cancer nanomedicine that has shown promise against brain and breast cancers in preclinical studies. In addition to the nanodrug, called Polycefin, the company has also developed a completely new versatile drug delivery platform that allows specific tumor targeting. The company provides cancer diagnostic and therapeutic tools based upon genomic analyses. and nanotechnology.